Liu Liang, Zhang Ying, Yu Shuangjiang, Yang Zhiming, He Chaoliang, Chen Xuesi
Key Laboratory of Polymer Ecomaterials, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, China.
University of Chinese Academy of Sciences, Beijing 100039, China.
ACS Biomater Sci Eng. 2018 Aug 13;4(8):2889-2902. doi: 10.1021/acsbiomaterials.8b00646. Epub 2018 Jul 17.
For enhanced oral insulin delivery, a strategy of acid-resistant and enteric hydrogels encapsulating insulin-loaded nanoparticles was developed. The nanoparticles were prepared by the formation of an anionic insulin/heparin sodium (Ins/HS) aggregate, followed by coating of chitosan (CS) on the surface. The nanoparticles, tagged as CS/Ins/HS NPs, exhibited excellent mucosa affinity, effective protease inhibition, and marked paracellular permeation enhancement. Moreover, to improve the acid-stability of CS/Ins/HS NPs and impart the capacity of intestine-targeted delivery, a pH- and amylase-responsive hydrogel was synthesized via free radical copolymerization, using methacrylic acid as the monomer and acrylate--carboxymethyl starch as the cross-linker. The resulting hydrogel exhibited sharp pH-sensitivity in the gastrointestinal tract and rapid enteric behavior under intestinal amylase. The additional protection for insulin in artificial gastric fluid was confirmed by packaging CS/Ins/HS NPs into the hydrogel. The obtained nanoparticle-incorporated hydrogel was named as NPs@Gel-2. The release of insulin from NPs@Gel-2 was evidently accelerated in artificial intestinal fluid containing α-amylase. Furthermore, the hypoglycemic effects were evaluated with type-1 diabetic rats. Compared to subcutaneous injection of insulin solution, the relative pharmacological availability (rPA) for oral intake of NPs@Gel-2 (30 IU/kg) was determined to be 8.6%, along with rPA of 4.6% for oral administration of unpackaged CS/Ins/HS NPs (30 IU/kg). Finally, the two-week therapeutic outcomes in diabetic rats were displayed after twice-daily treatments by oral intake of NPs@Gel-2, showing the relief of diabetic symptoms and suppression of weight loss in the rats. Therefore, this dual stimuli-responsive nanoparticle-incorporated hydrogel system could be a promising platform for oral insulin delivery.
为了增强口服胰岛素递送效果,开发了一种包封载胰岛素纳米颗粒的耐酸肠溶水凝胶策略。通过形成阴离子胰岛素/肝素钠(Ins/HS)聚集体制备纳米颗粒,随后在其表面包覆壳聚糖(CS)。标记为CS/Ins/HS NPs的纳米颗粒表现出优异的黏膜亲和力、有效的蛋白酶抑制作用以及显著的细胞旁渗透增强作用。此外,为了提高CS/Ins/HS NPs的酸稳定性并赋予肠道靶向递送能力,以甲基丙烯酸为单体、丙烯酸酯-羧甲基淀粉为交联剂,通过自由基共聚合成了一种pH和淀粉酶响应性水凝胶。所得水凝胶在胃肠道中表现出敏锐的pH敏感性,并在肠道淀粉酶作用下具有快速的肠溶行为。将CS/Ins/HS NPs包装入水凝胶中,证实了其对人工胃液中胰岛素的额外保护作用。所获得的纳米颗粒复合水凝胶命名为NPs@Gel-2。在含有α-淀粉酶的人工肠液中,NPs@Gel-2中胰岛素的释放明显加速。此外,对1型糖尿病大鼠进行了降血糖效果评估。与皮下注射胰岛素溶液相比,口服NPs@Gel-2(30 IU/kg)的相对药理利用率(rPA)为8.6%,口服未包装的CS/Ins/HS NPs(30 IU/kg)的rPA为4.6%。最后,通过每日两次口服NPs@Gel-2对糖尿病大鼠进行为期两周的治疗,显示出大鼠糖尿病症状得到缓解且体重减轻受到抑制。因此,这种双刺激响应性纳米颗粒复合水凝胶系统可能是一种有前景的口服胰岛素递送平台。